- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
The guidances released by the FDA to expand inclusion criteria for cancer clinical trials is a step in the right direction, said Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
The guidances released by the FDA to expand inclusion criteria for cancer clinical trials is a step in the right direction, said Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
Transcript
Last month, the FDA published 4 draft guidances and 1 final guidance to expand patient inclusion criteria for cancer clinical trials. Do you think this is a good step forward in having better representation in trials?
I think the FDA guidances were an important step in the right direction with regard to not limiting the patients quite so heavily that can participate in a trial. It’s a fine balance. We want patients to participate in a safe way, but we also know that these drugs, we hope, will be approved and therefore given to patients in the general patient population. So, we don’t want to necessarily not know those other risks that might take place or we know that this drug will be given, for example, to patients who have a history of hepatitis or some other illness or comorbidity that we want to know that perhaps in a clinical trial setting and not later. So, it’s a balance; it’s an important conversation to be had. I think that we are moving in the right direction. I’ve not really seen it in action just yet, but I think that we all understand the need to not so tightly limit what patients can participate in a clinical trial and which ones can’t.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
